文献速递前列腺癌

PAM50基底-管腔分型在前列腺癌主动监测中预测疾病进展

Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST).
PubMed 文献 · BJU Int · 2026-02-27

在MAST前瞻性试验205例接受主动监测的前列腺癌患者中,128例有转录组数据用于PAM50分型,分为管腔A型46例、管腔B型26例和基底型56例。管腔B型患者的无分级进展生存期显著劣于管腔A型和基底型(中位1.7年 vs 2.9年,log-rank P=0.005),24个月时无进展生存率分别为34%、68%和63%。PAM50基底-管腔分型有望预测主动监测中的进展风险。

要点

  • 管腔B型患者中位无分级进展生存期仅1.7年,显著短于其他亚型。
  • 24个月主动监测时,管腔B型无进展生存率34%,管腔A型68%,基底型63%。
  • 管腔B型与SPOP和CHD1突变强相关。

核心结论

  • PAM50基底-管腔分型有望作为预测前列腺癌主动监测进展风险的分子分类工具。

研究设计与样本

  • 前瞻性迈阿密主动监测试验(MAST)纳入205例接受主动监测的前列腺癌患者,进行系列多参数MRI和活检(含MRI靶向和系统采样)。
  • 对每例活检的最高级别核心采用Decipher临床级转录组检测进行表达谱分析,并用PAM50分子亚型模型评估基底-管腔分型。
  • 128例患者有基线基底-管腔分类的转录组数据。

主要发现

  • PAM50分型识别出管腔A型46例、管腔B型26例和基底型56例。
  • Decipher评分在管腔A型最低,基底型居中,管腔B型最高。
  • 管腔B型患者无分级进展生存期(中位1.7年)劣于管腔A型和基底型(中位2.9年;log-rank P=0.005)。
  • 24个月主动监测时,管腔B型无分级进展生存率为34%,基底型为63%,管腔A型为68%。
  • 转录组分析显示各亚型富集谱不同,管腔B型与SPOP和CHD1突变强相关。

关键数值与推荐

  • PAM50分型:管腔A型46例、管腔B型26例、基底型56例。
  • 无分级进展生存期:管腔B型中位1.7年,管腔A型和基底型中位2.9年(log-rank P=0.005)。
  • 24个月无分级进展生存率:管腔B型34%,基底型63%,管腔A型68%。

临床怎么用

  • 对于接受主动监测的前列腺癌患者,可考虑采用PAM50基底-管腔分型辅助评估进展风险。
  • 管腔B型患者进展风险较高,可能需要更密切监测或积极干预。

局限性

  • 样本量较小。
  • 单中心研究设置。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate basal-luminal cell of origin subtyping using Prediction Analysis of Microarray of 50 genes (PAM50) genomic classification profiles for predicting disease progression in men undergoing active surveillance (AS) for prostate cancer (PCa). PATIENTS AND METHODS: In the prospective Miami Active Surveillance Trial (MAST) trial, 205 men undergoing AS received serial multiparametric magnetic resonance imaging (MRI) and biopsies, including MRI-targeted and systematic sampling. The highest-grade core from each biopsy was sent for expression profiling using Decipher, a clinical-grade transcriptome assay (Veracyte Inc., San Diego, CA, USA). Basal-luminal subtyping was evaluated using PAM50 molecular subtype models. PCa grade progression was compared across subtypes, as were gene mutation signatures, prognostic indices, and pathway activities. Kaplan-Meier curves, log-rank test, and multivariable Cox regression were used to assess association between PAM50 and grade progression. Heatmaps and volcano plots were rendered to illustrate potential mechanistical differences between PAM50 subtypes. RESULTS: Of the 205 patients, 128 had transcriptome data for baseline basal-luminal classification. PAM50 identified 46 Luminal A (LA), 26 Luminal B (LB), and 56 Basal subtypes. Decipher scores were lowest in LA, followed by Basal, and highest in LB. Grade progression-free survival was worse in patients with the LB subtype (median 1.7 years) compared to those with LA and Basal subtypes (median 2.9 years; log-rank P = 0.005); LB patients had grade progression-free survival of 34% by 24 months of AS, compared to 63% for Basal or 68% for LA. Transcriptome analysis showed distinct enrichment profiles for each subtype, with LB strongly associated with SPOP and CHD1 mutations. Limitations include small sample size and single-institution setting. CONCLUSION: The PAM50 basal-luminal subtyping shows promise as a molecular classification tool for predicting progression risk in PCa. This is one of the only prospective studies evaluating PAM50 subtyping for predicting cancer progression in a cohort of men undergoing AS for PCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Malpani A, Ryan JT, Yu H, et al. Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST). BJU Int. 2026. PMID: 41757539. doi:10.1111/bju.70202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。